https://www.biopharmawatch.com/news/ATNM/actinium-pharmaceuticals-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-04T21:05:00.000Z Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/IONS/pelacarsen-phase-3-results-lpahorizon BiopharmaWatch en 2026-09-04T20:41:00.000Z Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) https://www.biopharmawatch.com/news/NVS/novartis-lpa-horizon-phase-iii-results-pelacarsen BiopharmaWatch en 2026-09-04T20:30:00.000Z Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) https://www.biopharmawatch.com/news/RPID/rapid-micro-biosystems-investor-conferences-2026 BiopharmaWatch en 2026-09-04T20:05:00.000Z Rapid Micro Biosystems to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/NMAD/nomad-power-solutions-special-meeting-adjournment BiopharmaWatch en 2026-09-04T20:05:00.000Z NOMAD POWER SOLUTIONS ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF STOCKHOLDERS https://www.biopharmawatch.com/news/APMD/apnimed-inducement-grants-nasdaq-rule-5635 BiopharmaWatch en 2026-09-04T20:01:00.000Z Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) https://www.biopharmawatch.com/news/KNSA/kiniksa-pharmaceuticals-wells-fargo-conference-2026 BiopharmaWatch en 2026-09-04T20:01:00.000Z Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/INBX/inhibrx-webcast-inbrx-106-phase-2-results BiopharmaWatch en 2026-09-04T20:00:00.000Z Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study https://www.biopharmawatch.com/news/MDT/medtronic-executives-investor-conferences-2026 BiopharmaWatch en 2026-09-04T16:34:00.000Z Medtronic executives to speak at upcoming investor conferences https://www.biopharmawatch.com/news/PLRZ/polyrizon-closes-4-million-offering BiopharmaWatch en 2026-09-04T15:58:00.000Z Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement https://www.biopharmawatch.com/news/PHGE/biomx-zorronet-launches-ai-command-control-platform BiopharmaWatch en 2026-09-04T13:28:00.000Z BiomX: Zorronet Launches No-Code Control Over AI-Powered Autonomous Response Workflows https://www.biopharmawatch.com/news/MMSI/merit-medical-investor-conferences-september-2026 BiopharmaWatch en 2026-09-04T13:25:00.000Z Merit Medical to Participate in Upcoming Investors Conferences in September https://www.biopharmawatch.com/news/LEXX/lexaria-presents-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-04T13:21:24.000Z Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/LNAI/lunai-bioworks-correction-press-release BiopharmaWatch en 2026-09-04T13:20:00.000Z Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint https://www.biopharmawatch.com/news/IART/integra-lifesciences-presentation-wells-fargo-morgan-stanley-2026 BiopharmaWatch en 2026-09-04T13:15:00.000Z Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-secures-debt-facility-orbimed BiopharmaWatch en 2026-09-04T12:50:00.000Z Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million https://www.biopharmawatch.com/news/TARS/tarsus-acquisition-alkeus-pharmaceuticals-eye-care BiopharmaWatch en 2026-09-04T12:38:00.000Z Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care https://www.biopharmawatch.com/news/GOSS/gossamer-bio-presentation-cantor-healthcare-conference BiopharmaWatch en 2026-09-04T12:00:00.000Z Gossamer Bio to Present at Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/A/agilent-launch-s540md-slide-scanner-system BiopharmaWatch en 2026-09-04T12:00:00.000Z Agilent Expands Digital Pathology Offering with U.S. Launch of the Agilent S540MD Slide Scanner System https://www.biopharmawatch.com/news/SEER/radoff-jec-group-calls-gulyani-resign-seer-board BiopharmaWatch en 2026-09-04T12:00:00.000Z Radoff-JEC Group Calls on Meeta Gulyani to Immediately Resign from Seer, Inc.’s Board of Directors https://www.biopharmawatch.com/news/TRLV/trulieve-medical-cannabis-dispensary-dunwoody-georgia BiopharmaWatch en 2026-09-04T12:00:00.000Z Trulieve to Open Medical Cannabis Dispensary in Dunwoody, Georgia https://www.biopharmawatch.com/news/TYRA/tyra-biosciences-conference-call-dabogratinib-results BiopharmaWatch en 2026-09-04T12:00:00.000Z Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-poster-ers-2026-congress BiopharmaWatch en 2026-09-04T12:00:00.000Z Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress https://www.biopharmawatch.com/news/NTLA/intellia-therapeutics-morgan-stanley-conference-2026 BiopharmaWatch en 2026-09-04T12:00:00.000Z Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/CMND/clearmind-acquires-charging-robotics-stake BiopharmaWatch en 2026-09-04T11:32:00.000Z Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis https://www.biopharmawatch.com/news/GLAS/glass-house-brands-september-investor-conferences BiopharmaWatch en 2026-09-04T11:30:00.000Z Glass House Brands to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/MGRO/mustgrow-officer-appointment-dsus-grant BiopharmaWatch en 2026-09-04T11:00:00.000Z MustGrow Announces Officer Appointment and Grant of DSUs https://www.biopharmawatch.com/news/BSEM/biostem-technologies-vendaje-access-vizient-premier BiopharmaWatch en 2026-09-04T11:00:00.000Z BioStem Technologies Opens Hospital Access for VENDAJE® and VENDAJE AC® Through Vizient and Premier https://www.biopharmawatch.com/news/VRXA/veraxa-biotech-appoints-raju-willener-cfo BiopharmaWatch en 2026-09-04T11:00:00.000Z VERAXA Biotech Appoints Raju Willener as Chief Financial Officer https://www.biopharmawatch.com/news/TFX/teleflex-dynetic35-stent-cirse-2026 BiopharmaWatch en 2026-09-04T10:30:00.000Z Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026 https://www.biopharmawatch.com/news/IMRN/immuron-launch-proibs-us-market BiopharmaWatch en 2026-09-04T10:00:00.000Z Immuron to launch PROIBS® in the United States https://www.biopharmawatch.com/blog/biotech-companies-by-disease-map-2026 BiopharmaWatch en 2026-09-04T09:22:57.162Z Biotech Companies by Disease: Mapping $672B Across 299 Indications https://www.biopharmawatch.com/news/JAGX/jaguar-health-crofelemer-infant-patient-compassionate-use BiopharmaWatch en 2026-09-04T08:30:00.000Z Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) https://www.biopharmawatch.com/news/MODD/modular-medical-contract-national-pbm-pivot-pump BiopharmaWatch en 2026-09-04T08:00:00.000Z Modular Medical Announces Contract with National U.S. Pharmacy Benefit Manager, Expanding Access to Pivot Tubeless Patch Pump https://www.biopharmawatch.com/news/MODD/modular-medical-webinar-launch-pivot BiopharmaWatch en 2026-09-04T00:00:00.000Z Registration is Now Open for Tribe Public's CEO Presentation and Q&A Webinar Event Titled ''The Road To Revenue: Modular Medical's Strategy For Launching Pivot'' Featuring Modular Medical CEO - Friday, September 4, 2026 https://www.biopharmawatch.com/news/IONS/zanvastro-fda-approval-alexander-disease BiopharmaWatch en 2026-09-03T23:47:00.000Z ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients https://www.biopharmawatch.com/news/BIIB/zorevunersen-dravet-syndrome-eec-2023 BiopharmaWatch en 2026-09-03T23:30:07.000Z Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) https://www.biopharmawatch.com/news/STOK/stoke-therapeutics-biogen-zorevunersen-dravet-syndrome-eec BiopharmaWatch en 2026-09-03T23:30:00.000Z Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) https://www.biopharmawatch.com/news/MANE/veradermics-september-investor-conferences BiopharmaWatch en 2026-09-03T21:33:00.000Z Veradermics to Present at Upcoming September Investor Conferences https://www.biopharmawatch.com/news/RVP/retractable-technologies-supports-onsore-manufacturing-act BiopharmaWatch en 2026-09-03T21:25:00.000Z Retractable Technologies, Inc. Supports Senator Blackburn’s ONSHORE Manufacturing Act https://www.biopharmawatch.com/news/OILS/nextleaf-solutions-fiscal-q3-2026-results BiopharmaWatch en 2026-09-03T21:01:00.000Z Nextleaf Solutions Reports Fiscal Q3 2026 Financial Results https://www.biopharmawatch.com/news/CTKB/cytek-biosciences-spectral-flow-cytometry-escca-iccs BiopharmaWatch en 2026-09-03T21:00:00.000Z Cytek® Biosciences Highlights the Expanding Role of Spectral Flow Cytometry in Clinical Research at ESCCA and ICCS https://www.biopharmawatch.com/news/TDOC/teladoc-health-inducement-awards-cfo BiopharmaWatch en 2026-09-03T20:35:00.000Z Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08 https://www.biopharmawatch.com/news/DBVT/dbv-technologies-september-investor-conferences BiopharmaWatch en 2026-09-03T20:32:00.000Z DBV Technologies to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/BIAF/bioaffinity-technologies-hc-wainwright-conference BiopharmaWatch en 2026-09-03T20:30:00.000Z bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/GMED/globus-medical-ce-mark-excelsius3d-imaging-system BiopharmaWatch en 2026-09-03T20:30:00.000Z Globus Medical Announces CE Mark for Excelsius3D™ Imaging System https://www.biopharmawatch.com/news/IQV/iqvia-predictive-clinical-development-efficiencies BiopharmaWatch en 2026-09-03T20:15:00.000Z IQVIA's Predictive Clinical Development Provides Sponsors With Significant Efficiencies to Get Treatments to Market Faster https://www.biopharmawatch.com/news/VANI/vivani-medical-investor-conferences-2026 BiopharmaWatch en 2026-09-03T20:08:00.000Z Vivani Medical Announces Participation in Upcoming Investor Conferences https://www.biopharmawatch.com/news/AGMB/agomab-participate-investor-conferences-september-2026 BiopharmaWatch en 2026-09-03T20:05:48.000Z Agomab to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ALEC/alector-participate-upcoming-healthcare-conferences BiopharmaWatch en 2026-09-03T20:05:00.000Z Alector to Participate in Upcoming Healthcare Conferences https://www.biopharmawatch.com/news/IRWD/ironwood-participate-wells-fargo-healthcare-conference BiopharmaWatch en 2026-09-03T20:05:00.000Z Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/CNTB/connect-biopharma-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-03T20:05:00.000Z Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/KTTA/pasithea-therapeutics-september-2026-investor-conferences BiopharmaWatch en 2026-09-03T20:05:00.000Z Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences https://www.biopharmawatch.com/news/IMRX/immuneering-participate-investor-conferences BiopharmaWatch en 2026-09-03T20:05:00.000Z Immuneering to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PCVX/vaxcyte-appoints-cmo-and-clo-narrows-vax-31-data-guidance BiopharmaWatch en 2026-09-03T20:05:00.000Z Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data https://www.biopharmawatch.com/news/CV/capsovision-participate-upcoming-investor-conferences BiopharmaWatch en 2026-09-03T20:05:00.000Z CapsoVision to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-upcoming-september-investor-events BiopharmaWatch en 2026-09-03T20:05:00.000Z LB Pharmaceuticals to Participate in Upcoming September Investor Events https://www.biopharmawatch.com/news/WVE/wave-life-sciences-cantor-2026-conference BiopharmaWatch en 2026-09-03T20:05:00.000Z Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference https://www.biopharmawatch.com/news/BSEM/biostem-technologies-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-03T20:05:00.000Z BioStem Technologies to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/SYRE/spyre-therapeutics-september-investor-conferences BiopharmaWatch en 2026-09-03T20:05:00.000Z Spyre Therapeutics to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/LFCR/lifecore-biomedical-participate-cphi-global-conference BiopharmaWatch en 2026-09-03T20:05:00.000Z Lifecore Biomedical to Participate at CPHI Global Conference https://www.biopharmawatch.com/news/LTGO/latigo-biotherapeutics-q2-2026-results-highlights BiopharmaWatch en 2026-09-03T20:05:00.000Z Latigo Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights https://www.biopharmawatch.com/news/RNTX/rein-therapeutics-september-investor-conferences BiopharmaWatch en 2026-09-03T20:01:00.000Z Rein Therapeutics to Present at Upcoming September Investor Conferences https://www.biopharmawatch.com/news/XENE/xenon-presents-wells-fargo-healthcare-conference BiopharmaWatch en 2026-09-03T20:01:00.000Z Xenon to Present at Wells Fargo Healthcare Conference https://www.biopharmawatch.com/news/CVS/updated-covid-19-vaccines-cvs-pharmacy-minuteclinic BiopharmaWatch en 2026-09-03T18:00:00.000Z Updated COVID-19 vaccines available at CVS Pharmacy and MinuteClinic across the U.S. https://www.biopharmawatch.com/news/NUS/nu-skin-ranked-worlds-number-one-beauty-wellness-devices BiopharmaWatch en 2026-09-03T15:00:00.000Z Nu Skin Ranked the World’s #1 Company for Beauty and Wellness Device Systems for Third Consecutive Year https://www.biopharmawatch.com/news/MIST/milestone-pharmaceuticals-nmpa-approval-etripamil-china BiopharmaWatch en 2026-09-03T13:35:00.000Z Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States https://www.biopharmawatch.com/news/COSM/cosmos-health-transformation-2026 BiopharmaWatch en 2026-09-03T13:30:00.000Z Cosmos Health: A Company Transformed — 2026 Year-to-Date https://www.biopharmawatch.com/news/ABBV/abbvie-phase-3-cervino-trial-results-etentamig BiopharmaWatch en 2026-09-03T13:15:00.000Z AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma https://www.biopharmawatch.com/news/LGVN/longeveron-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-03T13:15:00.000Z Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/HCTI/hcti-distributes-minority-interest-teyame-ai-holdings BiopharmaWatch en 2026-09-03T13:05:00.000Z Healthcare Triangle, Inc. to Distribute Minority Interest of Teyame AI Holdings Inc. Common Shares in Stock Dividend Distribution to HCTI Shareholders, In Connection with its Planned Direct Listing. https://www.biopharmawatch.com/news/LIVN/livanova-presents-morgan-stanley-baird-conferences-september BiopharmaWatch en 2026-09-03T13:00:00.000Z LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September https://www.biopharmawatch.com/news/CYH/community-health-systems-2026-impact-report BiopharmaWatch en 2026-09-03T13:00:00.000Z Community Health Systems Releases 2026 Community Impact Report https://www.biopharmawatch.com/news/ALC/alcon-launches-unity-m-ophthalmic-microscope BiopharmaWatch en 2026-09-03T13:00:00.000Z Alcon Launches UNITY M, a Premium Ophthalmic Microscope Delivering Precise Control https://www.biopharmawatch.com/news/CODX/co-diagnostics-cloud-infrastructure-india BiopharmaWatch en 2026-09-03T13:00:00.000Z Co-Diagnostics Launches Integrated Cloud and Mobile Infrastructure in India https://www.biopharmawatch.com/news/PALI/palisade-bio-investor-conferences-september-2026 BiopharmaWatch en 2026-09-03T13:00:00.000Z Palisade Bio to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/PLRZ/polyrizon-4-million-offering-private-placement BiopharmaWatch en 2026-09-03T12:50:00.000Z Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement https://www.biopharmawatch.com/news/APGE/abbvie-completes-acquisition-apogee-therapeutics BiopharmaWatch en 2026-09-03T12:34:00.000Z AbbVie Completes Acquisition of Apogee Therapeutics https://www.biopharmawatch.com/news/ORBS/eightco-holdings-reports-380-million-holdings BiopharmaWatch en 2026-09-03T12:30:00.000Z Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately $380 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Nearly 302 Million WLD Tokens https://www.biopharmawatch.com/news/CTXR/citius-pharmaceuticals-september-2026-investor-conferences BiopharmaWatch en 2026-09-03T12:30:00.000Z Citius Pharmaceuticals to Participate in September 2026 Investor Conferences https://www.biopharmawatch.com/news/TLPH/talphera-hc-wainwright-investment-conference-2026 BiopharmaWatch en 2026-09-03T12:30:00.000Z Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/FBLG/fibrobiologics-new-patent-fibroblasts-wound-healing BiopharmaWatch en 2026-09-03T12:30:00.000Z FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing https://www.biopharmawatch.com/news/KALA/kala-virotek-exclusive-distribution-agreement BiopharmaWatch en 2026-09-03T12:30:00.000Z Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program https://www.biopharmawatch.com/news/BBLG/bone-biologics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-03T12:30:00.000Z Bone Biologics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/NXL/nexalin-technology-alzheimers-study-analysis BiopharmaWatch en 2026-09-03T12:30:00.000Z Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study https://www.biopharmawatch.com/news/CRVS/corvus-pharmaceuticals-2026-cantor-conference BiopharmaWatch en 2026-09-03T12:30:00.000Z Corvus Pharmaceuticals to Present at the 2026 Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/MDLN/medline-participation-morgan-stanley-healthcare-conference BiopharmaWatch en 2026-09-03T12:30:00.000Z Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/ONCO/onconetix-acquisition-realbotix-humanoid-robots-pilot BiopharmaWatch en 2026-09-03T12:30:00.000Z Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events https://www.biopharmawatch.com/news/PROF/profound-medical-lake-street-conference-2026 BiopharmaWatch en 2026-09-03T12:15:00.000Z Profound Medical to Participate in Lake Street’s 10th Annual Best Ideas Growth Conference https://www.biopharmawatch.com/news/SRXH/srx-global-armr-sciences-shareholder-update BiopharmaWatch en 2026-09-03T12:15:00.000Z SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company https://www.biopharmawatch.com/news/ABBV/abbvie-presents-morgan-stanley-healthcare-conference-2026 BiopharmaWatch en 2026-09-03T12:05:00.000Z AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference https://www.biopharmawatch.com/news/HRMY/harmony-biosciences-poster-presentations-european-epilepsy-congress BiopharmaWatch en 2026-09-03T12:05:00.000Z Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress https://www.biopharmawatch.com/news/SXTP/60-degrees-pharmaceuticals-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-03T12:04:00.000Z 60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-nasdaq-ld-micro-summit-2026 BiopharmaWatch en 2026-09-03T12:00:00.000Z Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 https://www.biopharmawatch.com/news/ANIX/anixa-biosciences-presentation-nasdaq-ld-micro-summit BiopharmaWatch en 2026-09-03T12:00:00.000Z Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 https://www.biopharmawatch.com/news/MENS/jyong-biotech-stockfan-virtual-investor-roadshow BiopharmaWatch en 2026-09-03T12:00:00.000Z Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow https://www.biopharmawatch.com/news/NSPR/inspiremd-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-03T12:00:00.000Z InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/REPL/replimune-present-cantor-global-healthcare-conference-2026 BiopharmaWatch en 2026-09-03T12:00:00.000Z Replimune to Present at the Cantor Global Healthcare Conference 2026 https://www.biopharmawatch.com/news/TECX/tectonic-therapeutic-morgan-stanley-conference BiopharmaWatch en 2026-09-03T12:00:00.000Z Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference https://www.biopharmawatch.com/news/LBRX/lb-pharmaceuticals-appoints-joseph-miller-cfo BiopharmaWatch en 2026-09-03T12:00:00.000Z LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officer https://www.biopharmawatch.com/news/NVCT/nuvectis-pharma-investor-conferences-2026 BiopharmaWatch en 2026-09-03T12:00:00.000Z Nuvectis Pharma To Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/BMEA/biomea-fusion-investor-conferences-2026 BiopharmaWatch en 2026-09-03T12:00:00.000Z Biomea Fusion to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/CVKD/cadrenal-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-03T12:00:00.000Z Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/OVID/ovid-therapeutics-investor-conferences-2026 BiopharmaWatch en 2026-09-03T12:00:00.000Z Ovid Therapeutics to Participate in Upcoming Investor Conferences https://www.biopharmawatch.com/news/ALT/altimmune-wells-fargo-healthcare-conference-2026 BiopharmaWatch en 2026-09-03T12:00:00.000Z Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference https://www.biopharmawatch.com/news/QNCX/quince-therapeutics-september-2026-investor-conferences BiopharmaWatch en 2026-09-03T12:00:00.000Z Quince Therapeutics to Participate in September 2026 Investor Conferences https://www.biopharmawatch.com/news/ACRS/aclaris-therapeutics-2026-cantor-conference BiopharmaWatch en 2026-09-03T12:00:00.000Z Aclaris Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/KRYS/krystal-biotech-2026-cantor-conference BiopharmaWatch en 2026-09-03T12:00:00.000Z Krystal Biotech to Present at 2026 Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/GRCE/grace-therapeutics-hc-wainwright-conference-2026 BiopharmaWatch en 2026-09-03T12:00:00.000Z Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/STXS/university-szeged-robotic-cardiology-program-launch BiopharmaWatch en 2026-09-03T11:56:00.000Z University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program https://www.biopharmawatch.com/news/EBS/emergent-biosolutions-repurchases-senior-unsecured-notes BiopharmaWatch en 2026-09-03T11:45:00.000Z Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes https://www.biopharmawatch.com/news/HELP/helus-pharma-cantor-healthcare-conference-2026 BiopharmaWatch en 2026-09-03T11:30:36.000Z Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York https://www.biopharmawatch.com/news/LQDA/fda-fast-track-yutrepia-raynauds-phenomenon BiopharmaWatch en 2026-09-03T11:30:00.000Z FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis https://www.biopharmawatch.com/news/ARWR/arrowhead-pharmaceuticals-september-2026-investor-conferences BiopharmaWatch en 2026-09-03T11:30:00.000Z Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences https://www.biopharmawatch.com/news/GPCR/structure-therapeutics-upcoming-healthcare-conferences BiopharmaWatch en 2026-09-03T11:30:00.000Z Structure Therapeutics to Participate in Upcoming Healthcare Investor Conferences https://www.biopharmawatch.com/news/DYN/dyne-therapeutics-preclinical-data-dmd-nmsg-meeting BiopharmaWatch en 2026-09-03T11:30:00.000Z Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting https://www.biopharmawatch.com/news/EIKN/eikon-therapeutics-appoints-ching-pin-chang-cso BiopharmaWatch en 2026-09-03T11:30:00.000Z Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer https://www.biopharmawatch.com/news/ADCT/adc-therapeutics-2026-cantor-global-healthcare-conference BiopharmaWatch en 2026-09-03T11:15:00.000Z ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/ATHE/alterity-therapeutics-fireside-chat-cantor-conference-2026 BiopharmaWatch en 2026-09-03T11:05:00.000Z Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 https://www.biopharmawatch.com/news/DTR/diagnostear-fda-pre-submission-tearx-red-eye-test BiopharmaWatch en 2026-09-03T11:00:00.000Z DiagnosTear Technologies Announces FDA Pre-Submission for TeaRx(TM) Red Eye Diagnostic Test https://www.biopharmawatch.com/news/BHST/bioharvest-sciences-dual-listing-tel-aviv-stock-exchange BiopharmaWatch en 2026-09-03T11:00:00.000Z BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) https://www.biopharmawatch.com/news/CTSO/cytosorbents-reverse-stock-split-nasdaq-compliance BiopharmaWatch en 2026-09-03T11:00:00.000Z CytoSorbents Announces Reverse Stock Split https://www.biopharmawatch.com/news/INSM/insmed-data-presentation-ers-congress-2026 BiopharmaWatch en 2026-09-03T11:00:00.000Z Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 https://www.biopharmawatch.com/news/ARMP/armata-pharmaceuticals-phage-biology-publication BiopharmaWatch en 2026-09-03T11:00:00.000Z Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials https://www.biopharmawatch.com/news/FATE/fate-therapeutics-fireside-chat-2026-cantor-conference BiopharmaWatch en 2026-09-03T11:00:00.000Z Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference https://www.biopharmawatch.com/news/ELDN/eledon-pharmaceuticals-islet-cell-transplantation-ind-submission BiopharmaWatch en 2026-09-03T11:00:00.000Z Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 https://www.biopharmawatch.com/news/GYRE/gyre-therapeutics-september-investor-conferences BiopharmaWatch en 2026-09-03T11:00:00.000Z Gyre Therapeutics to Participate in Upcoming September Investor Conferences https://www.biopharmawatch.com/news/CCCC/c4-therapeutics-cemsidomide-biomarker-data-presentation BiopharmaWatch en 2026-09-03T11:00:00.000Z C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting https://www.biopharmawatch.com/news/LONA/leonabio-participate-cantor-global-healthcare-conference-2026 BiopharmaWatch en 2026-09-03T11:00:00.000Z LeonaBio to Participate in Cantor Global Healthcare Conference 2026 https://www.biopharmawatch.com/news/CLYM/climb-bio-clym116-phase-1-data-iga-nephropathy BiopharmaWatch en 2026-09-03T11:00:00.000Z Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy https://www.biopharmawatch.com/news/BLSM/blossomhill-therapeutics-conference-presentation BiopharmaWatch en 2026-09-03T11:00:00.000Z BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference https://www.biopharmawatch.com/news/ANIP/ani-pharmaceuticals-september-investor-conferences BiopharmaWatch en 2026-09-03T10:55:00.000Z ANI Pharmaceuticals to Present at September Investor Conferences https://www.biopharmawatch.com/news/PHVS/pharvaris-bradykinin-symposium-2026-data BiopharmaWatch en 2026-09-03T10:50:00.000Z Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026 https://www.biopharmawatch.com/news/HEAL/restart-life-sciences-reports-q2-2026-results BiopharmaWatch en 2026-09-03T10:00:00.000Z Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth https://www.biopharmawatch.com/news/APVO/aptevos-mipletamig-triplet-aml-results BiopharmaWatch en 2026-09-03T08:05:00.000Z Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML https://www.biopharmawatch.com/news/MODD/modular-medical-fda-clearance-pivot-pump-enhancements BiopharmaWatch en 2026-09-03T08:00:00.000Z Modular Medical Announces FDA Clearance of Pivot Tubeless Insulin Patch Pump Enhancements https://www.biopharmawatch.com/news/FTRE/fortrea-worldwide-clinical-trials-partnership BiopharmaWatch en 2026-09-03T07:52:00.000Z Fortrea เข้าซื้อกิจการหน่วยเภสัชวิทยาคลินิกและการปฏิบัติการห้องปฏิบัติการวิเคราะห์ทางชีวภาพจาก Worldwide Clinical Trials https://www.biopharmawatch.com/news/FTRE/fortrea-acquires-early-phase-services-worldwide-clinical-trials BiopharmaWatch en 2026-09-03T07:52:00.000Z Fortrea Akan Mengambil Alih Unit Farmakologi Klinikal dan Operasi Makmal Bioanalisis daripada Worldwide Clinical Trials https://www.biopharmawatch.com/news/FTRE/fortrea-worldwide-clinical-trials-collaboration BiopharmaWatch en 2026-09-03T07:52:00.000Z Fortrea, Worldwide Clinical Trials의 임상약리 유닛·생물분석 연구소 사업 인수 https://www.biopharmawatch.com/news/FTRE/fortrea-acquires-early-phase-services-worldwide BiopharmaWatch en 2026-09-03T07:52:00.000Z Fortrea Akan Mengakuisisi Unit Farmakologi Klinis dan Operasional Laboratorium Bionalitik dari Worldwide Clinical Trials https://www.biopharmawatch.com/news/FTRE/fortrea-acquires-worldwide-clinical-trials-early-phase-services BiopharmaWatch en 2026-09-03T07:52:00.000Z Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials https://www.biopharmawatch.com/news/BIIB/leqembi-subcutaneous-approval-china BiopharmaWatch en 2026-09-03T04:00:28.000Z LEQEMBI® (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China https://www.biopharmawatch.com/news/RVMD/phase-1-2-data-rasonque-nsclc BiopharmaWatch en 2026-09-02T21:50:00.000Z New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/SMMT/ivonescimab-harmoni-2-study-nsclc BiopharmaWatch en 2026-09-02T21:41:00.000Z Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China https://www.biopharmawatch.com/news/VCTR/investigation-victory-capital-merger-first-eagle BiopharmaWatch en 2026-09-02T21:32:00.000Z $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Victory Capital Holdings, Inc. (NASDAQ: VCTR) https://www.biopharmawatch.com/news/SOAR/shareholder-alert-volato-group-investigation BiopharmaWatch en 2026-09-02T21:29:00.000Z $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Volato Group, Inc. (NYSE American: SOAR)